Does stimulant treatment of attention-deficit/hyperactivity disorder affect the risk of subsequent substance use through adolescence into early adulthood?
This study found no evidence that stimulant treatment for ADHD is associated with an increased or decreased risk of self-reported substance use through adolescence into early adulthood. See the synopsis for a discussion of possible reporting biases.
Plan de l'etude:
This study addresses whether stimulant treatment for attention-deficit/hyperactivity disorder (ADHD) in childhood increases or decreases the risk of subsequent substance abuse. The investigators analyzed follow-up data obtained from a randomized trial of medical and behavioral therapy for ADHD that started in 1994 with follow-up continuing until the patients' mean age of 25 years. Study participants (n = 579; 61% were White, 80% were male) included children aged 7 to 9 years who met standard diagnostic criteria for ADHD. Self-reported data on substance use through adolescence and early adulthood occurred for 81.3% of participants at least once in adulthood. No attempts occurred to verify prescription history or laboratory-based drug level determinations. In addition, individuals who did not provide follow-up may be more likely to have a history of substance abuse. After multiple adjustments for potential confounders, no significant association occurred between stimulant treatment and the risk of subsequent heavy alcohol use, marijuana use, tobacco use, and other substance use.
David C. Slawson, MD
Professor and Vice Chair of Family Medicine for Education and Scholarship
Professor of Family Medicine, UNC Chapel Hill